Citadel Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Citadel Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$270K	Buy	+6,181	New	+$286K	﹤0.01%	10705
2025 Q2	–	Sell	-3,213	Closed	-$102K	–	13466
2025 Q1	$102K	Sell	3,213 -591	-16%	-$22.4K	﹤0.01%	11425
2024 Q4	$148K	Buy	+3,804	New	+$160K	﹤0.01%	10909
2024 Q2	–	Sell	-4,016	Closed	-$183K	–	14697
2024 Q1	$183K	Buy	+4,016	New	+$183K	﹤0.01%	10456
2023 Q1	–	Sell	-3,518	Closed	-$178K	–	15001
2022 Q4	$178K	Buy	+3,518	New	+$181K	﹤0.01%	10340
2022 Q1	–	Sell	-4,860	Closed	-$386K	–	13966
2021 Q4	$386K	Sell	4,860 -1,657	-25%	-$139K	﹤0.01%	10305
2021 Q3	$580K	Buy	6,517 +2,598	+66%	+$243K	﹤0.01%	9512
2021 Q2	$390K	Buy	+3,919	New	+$348K	﹤0.01%	10629
2021 Q1	–	Sell	-5,368	Closed	-$509K	–	13371
2020 Q4	$509K	Buy	+5,368	New	+$449K	﹤0.01%	8108
2020 Q3	–	Sell	-7,957	Closed	-$559K	–	10298
2020 Q2	$559K	Buy	+7,957	New	+$496K	﹤0.01%	6879

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Citadel Advisors's GNOM Position: Q1 2026 in Review

Citadel Advisors opened a new position in Global X Genomics & Biotechnology ETF (GNOM) in Q1 2026: 6,181 shares worth $270K. The stake represents ﹤0.01% of the portfolio and ranks #10705 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in GNOM as recently as Q1 2025.

Citadel Advisors first reported a position in GNOM in Q2 2020 and has held it in 10 quarters since. The position peaked at $580K in Q3 2021. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

Citadel Advisors held 6,181 shares of Global X Genomics & Biotechnology ETF worth $270K as of Q1 2026.
Global X Genomics & Biotechnology ETF was a new Citadel Advisors position in Q1 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10705 holding.
Citadel Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2020 and has held it in 10 quarters since.
Citadel Advisors's Global X Genomics & Biotechnology ETF position peaked at $580K in Q3 2021.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.